MX2024009828A - Uso de roluperidona en la prevencion de recaidas en pacientes con esquizofrenia. - Google Patents
Uso de roluperidona en la prevencion de recaidas en pacientes con esquizofrenia.Info
- Publication number
- MX2024009828A MX2024009828A MX2024009828A MX2024009828A MX2024009828A MX 2024009828 A MX2024009828 A MX 2024009828A MX 2024009828 A MX2024009828 A MX 2024009828A MX 2024009828 A MX2024009828 A MX 2024009828A MX 2024009828 A MX2024009828 A MX 2024009828A
- Authority
- MX
- Mexico
- Prior art keywords
- roluperidone
- preventing relapse
- schizophrenia patients
- schizophrenia
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263309874P | 2022-02-14 | 2022-02-14 | |
| PCT/US2023/062500 WO2023154927A1 (en) | 2022-02-14 | 2023-02-13 | Use of roluperidone in preventing relapse in schizophrenia patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009828A true MX2024009828A (es) | 2024-11-08 |
Family
ID=85569991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009828A MX2024009828A (es) | 2022-02-14 | 2024-08-12 | Uso de roluperidona en la prevencion de recaidas en pacientes con esquizofrenia. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230255953A1 (https=) |
| EP (2) | EP4479049B1 (https=) |
| JP (1) | JP2025505261A (https=) |
| KR (1) | KR20240161650A (https=) |
| CN (1) | CN118984705A (https=) |
| AU (1) | AU2023217097A1 (https=) |
| CA (1) | CA3243767A1 (https=) |
| CL (1) | CL2024002418A1 (https=) |
| ES (1) | ES3064313T3 (https=) |
| IL (1) | IL314859A (https=) |
| MX (1) | MX2024009828A (https=) |
| WO (1) | WO2023154927A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166617B2 (en) | 2000-02-29 | 2007-01-23 | Mitsubishi Pharma Corporation | Cyclic amide derivatives |
| PL3227273T3 (pl) | 2014-12-02 | 2022-05-30 | Minerva Neurosciences, Inc. | Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii |
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
| WO2020264486A1 (en) * | 2019-06-28 | 2020-12-30 | Teva Czech Industries S.R.O | Solid state forms of roluperidone and salts thereof |
-
2023
- 2023-02-13 EP EP23710619.0A patent/EP4479049B1/en active Active
- 2023-02-13 JP JP2024547680A patent/JP2025505261A/ja active Pending
- 2023-02-13 AU AU2023217097A patent/AU2023217097A1/en active Pending
- 2023-02-13 US US18/168,028 patent/US20230255953A1/en active Pending
- 2023-02-13 WO PCT/US2023/062500 patent/WO2023154927A1/en not_active Ceased
- 2023-02-13 EP EP25223916.5A patent/EP4729122A2/en active Pending
- 2023-02-13 KR KR1020247031088A patent/KR20240161650A/ko active Pending
- 2023-02-13 IL IL314859A patent/IL314859A/en unknown
- 2023-02-13 CA CA3243767A patent/CA3243767A1/en active Pending
- 2023-02-13 CN CN202380033205.7A patent/CN118984705A/zh active Pending
- 2023-02-13 ES ES23710619T patent/ES3064313T3/es active Active
-
2024
- 2024-08-12 CL CL2024002418A patent/CL2024002418A1/es unknown
- 2024-08-12 MX MX2024009828A patent/MX2024009828A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3243767A1 (en) | 2023-08-17 |
| WO2023154927A1 (en) | 2023-08-17 |
| EP4479049B1 (en) | 2025-12-17 |
| US20230255953A1 (en) | 2023-08-17 |
| EP4729122A2 (en) | 2026-04-22 |
| JP2025505261A (ja) | 2025-02-21 |
| IL314859A (en) | 2024-10-01 |
| AU2023217097A1 (en) | 2024-08-29 |
| CL2024002418A1 (es) | 2024-12-13 |
| EP4479049A1 (en) | 2024-12-25 |
| CN118984705A (zh) | 2024-11-19 |
| ES3064313T3 (en) | 2026-04-23 |
| KR20240161650A (ko) | 2024-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002497A1 (es) | Uso de inhibidores de bet como tratamiento para la mielofibrosis | |
| MX2025011553A (es) | Composiciones para inducir la hidrolisis de ras gtp y sus usos | |
| MX2022000143A (es) | Metodos novedosos. | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
| CO2026004333A2 (es) | Inhibidores de ras-pi3k para el tratamiento del cáncer y enfermedades inmunológicas | |
| BR112022026186A2 (pt) | Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras | |
| UY31017A1 (es) | Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica. | |
| MX2024009828A (es) | Uso de roluperidona en la prevencion de recaidas en pacientes con esquizofrenia. | |
| BRPI0513168A (pt) | memantina como tratamento adjunto para antipsicóticos atìpicos em pacientes com esquizofrenia | |
| CO2024012870A2 (es) | Tratamiento de neurofibromas cutáneos con mirdametinib | |
| PE20211199A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| BR112021020505A2 (pt) | Composição de dentifrício para higiene oral e uso de um sal de zinco | |
| BR112023002883A2 (pt) | Conjunto de composições para tratamento bucal anticárie | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| MX2022003010A (es) | Tratamiento de la emr mediante cambio de terapia. | |
| BR112021018815A2 (pt) | Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário | |
| CR20230472A (es) | Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos | |
| MX2025006345A (es) | Venglustat junto con un inhibidor fuerte o moderado de cyp3a4 | |
| CO2025006782A2 (es) | Composición farmacéutica para la prevención o tratamiento contra úlcera péptica relacionada a fármacos, que comprende zastaprazán o una sal farmacéuticamente aceptable del mismo | |
| MX2022011651A (es) | Composicion farmaceutica para tratamiento de diabetes. |